

=> s neurotroph?(1)pyrrolidin?  
17085 NEUROTROPH?  
60174 PYRROLIDIN?  
L1 31 NEUROTROPH?(L) PYRROLIDIN?

=> s 11 and py<1998  
18297841 PY<1998  
L2 4 L1 AND PY<1998

=> d bib hit 1-4

L2 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2002:332684 CAPLUS  
DN 136:340999  
TI Preparation of amino acid derivatives as rotamase enzyme activity  
inhibitors  
IN Steiner, Joseph P.; Hamilton, Gregory S.  
PA USA  
SO U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 359,351.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 8

|    | PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE         |
|----|---------------|------|----------|-----------------|--------------|
| PI | US 2002052410 | A1   | 20020502 | US 2001-805249  | 20010314     |
|    | US 5614547    | A    | 19970325 | US 1995-479436  | 19950607 <-- |
|    | US 2002013344 | A1   | 20020131 | US 1995-551026  | 19951031     |
|    | RU 2269514    | C2   | 20060210 | RU 2000-115383  | 19960605     |
|    | US 6509477    | B1   | 20030121 | US 1999-359351  | 19990721     |

|      |                |    |          |
|------|----------------|----|----------|
| PRAI | US 1995-479436 | A1 | 19950607 |
|      | US 1995-551026 | A2 | 19951031 |
|      | US 1996-693003 | B1 | 19960806 |
|      | US 1999-359351 | A2 | 19990721 |
|      | RU 1997-111860 | A3 | 19960605 |

OS MARPAT 136:340999

|    | PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE         |
|----|---------------|------|----------|-----------------|--------------|
| PI | US 2002052410 | A1   | 20020502 | US 2001-805249  | 20010314     |
|    | US 5614547    | A    | 19970325 | US 1995-479436  | 19950607 <-- |
|    | US 2002013344 | A1   | 20020131 | US 1995-551026  | 19951031     |
|    | RU 2269514    | C2   | 20060210 | RU 2000-115383  | 19960605     |
|    | US 6509477    | B1   | 20030121 | US 1999-359351  | 19990721     |

AB The invention relates to methods of using **neurotrophic** compds.  
having an affinity for FKBP-type immunophilins to stimulate or promote  
neuronal growth or regeneration and to prevent neuronal degeneration.  
Amino acid derivs. R1C(:X)CON(J)CHKCO-Y(CH2)nCHZR2 [n = 0-3; Y is CH2, O,  
NH, or alkylimino; Z and R2 are independently Ar, or cycloalkyl,  
cycloalkenyl, or Ar-(un)substituted alkyl or alkenyl, or TCH:C(Q)CH2-,  
where Q = H, alkyl or alkenyl; T is Ar or substituted cycloalkyl; Ar is an  
(un)substituted mono or bicyclic heterocyclic aromatic ring; R1 is U, where U  
is H, (un)substituted alkyl, alkoxy, alkenyl, alkenyloxy, cycloalkyl or  
cycloalkenyl; X is O or CH-U, provided that if R1 is H, then X is CH-U or  
if X is O then R1 is U; J is H, alkyl or benzyl; K is alkyl, benzyl or  
cyclohexylethyl; or J and K may be taken together to form a 5-7 membered  
heterocyclic ring which may contain O, S, SO or SO2] or their  
pharmaceutically acceptable salts are claimed. Thus, 3-(3,4,5-  
trimethoxyphenyl)propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-  
**pyrrolidinecarboxylate** was prepared by esterification of the acid  
and showed Ki = 0.025  $\mu$ M for inhibition of rotamase and ED50 = 80 nM  
for neurite outgrowth in chick dorsal root ganglion (DRG) cultures.

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:276521 CAPLUS  
 DN 136:310178  
 TI Preparation of amino acid derivatives as rotamase enzyme activity inhibitors  
 IN Steiner, Joseph P.; Hamilton, Gregory S.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 551,026.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 8

|      | PATENT NO.        | KIND | DATE     | APPLICATION NO. | DATE         |
|------|-------------------|------|----------|-----------------|--------------|
| PI   | US 2002042377     | A1   | 20020411 | US 2001-873298  | 20010605     |
|      | US 5614547        | A    | 19970325 | US 1995-479436  | 19950607 <-- |
|      | US 2002013344     | A1   | 20020131 | US 1995-551026  | 19951031     |
|      | RU 2269514        | C2   | 20060210 | RU 2000-115383  | 19960605     |
|      | US 6509477        | B1   | 20030121 | US 1999-359351  | 19990721     |
| PRAI | US 1995-479436    | A1   | 19950607 |                 |              |
|      | US 1995-551026    | A2   | 19951031 |                 |              |
|      | US 1996-693003    | B1   | 19960806 |                 |              |
|      | US 1999-359351    | A2   | 19990721 |                 |              |
|      | RU 1997-111860    | A3   | 19960605 |                 |              |
| OS   | MARPAT 136:310178 |      |          |                 |              |
|      | PATENT NO.        | KIND | DATE     | APPLICATION NO. | DATE         |
| PI   | US 2002042377     | A1   | 20020411 | US 2001-873298  | 20010605     |
|      | US 5614547        | A    | 19970325 | US 1995-479436  | 19950607 <-- |
|      | US 2002013344     | A1   | 20020131 | US 1995-551026  | 19951031     |
|      | RU 2269514        | C2   | 20060210 | RU 2000-115383  | 19960605     |
|      | US 6509477        | B1   | 20030121 | US 1999-359351  | 19990721     |

AB The invention relates to methods of using **neurotrophic** compds. having an affinity for FKBP-type immunophilins to stimulate or promote neuronal growth or regeneration and to prevent neuronal degeneration. Amino acid derivs. R1C(:X)CON(J)CHKCO-Y-Z [Y is O, NH, or alkylimino; Z is H, CHL-Ar, alkyl, alkenyl, cycloalkyl, cycloalkenyl or Ar-substituted alkyl or alkenyl, or TCH:C(Q)CH(L)-, where L and Q are H, alkyl or alkenyl; T is Ar or substituted cyclohexyl; Ar is 1- or 2-naphthyl, 2- or 3-furyl, 2-thienyl, 2-, 3- or 4-pyridyl, (un)substituted phenyl; R1 is U, where U is H, (un)substituted alkyl, alkoxy, alkenyl, alkenyloxy, cycloalkyl or cycloalkenyl; X is O or CH-U, provided that if R1 is H, then X is CH-U or if X is O then R1 is U; J is H, alkyl or benzyl; K is alkyl, benzyl or cyclohexylethyl; or J and K may be taken together to form a 5-7 membered heterocyclic ring which may contain O, S, SO or SO2] or their pharmaceutically acceptable salts are claimed. Thus, 3-(3,4,5-trimethoxyphenyl)propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate was prepared by esterification of the acid and showed Ki = 0.025  $\mu$ M for inhibition of rotamase and ED50 = 80 nM for neurite outgrowth in chick dorsal root ganglion (DRG) cultures.

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:45148 CAPLUS  
 DN 130:110640  
 TI Preparation of proline derivatives as inhibitors of rotamase enzyme activity  
 IN Hamilton, Gregory S.; Steiner, Joseph P.  
 PA GPI NIL Holdings, Inc., USA  
 SO U.S., 27 pp., Cont.-in-part of U.S. 5,614,547.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 8

|  | PATENT NO. | KIND  | DATE  | APPLICATION NO. | DATE  |
|--|------------|-------|-------|-----------------|-------|
|  | -----      | ----- | ----- | -----           | ----- |

|    |   |    |          |                   |              |
|----|---|----|----------|-------------------|--------------|
| PI | US 5859031  | A  | 19990112 | US 1996-650461    | 19960521     |
|    | US 5614547  | A  | 19970325 | US 1995-479436    | 19950607 <-- |
|    | CA 2206799  | AA | 19961219 | CA 1996-2206799   | 19960605 <-- |
|    | CA 2206799  | C  | 20051227 |                   |              |
|    | CA 2352900  | AA | 19961219 | CA 1996-2352900   | 19960605 <-- |
|    | WO 9640633  | A1 | 19961219 | WO 1996-US9701    | 19960605 <-- |
|    | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG |    |          |                   |              |
|    | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN  |    |          |                   |              |
|    | AU 9661062  | A1 | 19961230 | AU 1996-61062     | 19960605 <-- |
|    | AU 703118   | B2 | 19990318 |                   |              |
|    | GB 2305176  | A1 | 19970402 | GB 1996-24257     | 19960605 <-- |
|    | GB 2305176  | B2 | 19991222 |                   |              |
|    | EP 769006   | A1 | 19970423 | EP 1996-918384    | 19960605 <-- |
|    | EP 769006   | B1 | 20001108 |                   |              |
|    | R: BE, FR, GR, IE, IT, MC, NL   |    |          |                   |              |
|    | DE 19680256   | T  | 19970619 | DE 1996-19680256  | 19960605 <-- |
|    | DE 19680256   | C2 | 20030430 |                   |              |
|    | CH 688775   | A  | 19980313 | CH 1996-2790      | 19960605     |
|    | CN 1187188  | A  | 19980708 | CN 1996-194554    | 19960605     |
|    | GB 2324527  | A1 | 19981028 | GB 1998-15112     | 19960605     |
|    | GB 2324527  | B2 | 19991222 |                   |              |
|    | GB 2325230  | A1 | 19981118 | GB 1998-17938     | 19960605     |
|    | BR 9608444  | A  | 19990105 | BR 1996-8444      | 19960605     |
|    | GB 2332673  | A1 | 19990630 | GB 1999-5606      | 19960605     |
|    | ES 2131457  | A1 | 19990716 | ES 1996-50030     | 19960605     |
|    | ES 2131457  | B1 | 20000401 |                   |              |
|    | JP 2000503626   | T2 | 20000328 | JP 1997-501958    | 19960605     |
|    | JP 3561843  | B2 | 20040902 |                   |              |
|    | EP 992492   | A1 | 20000412 | EP 1999-126231    | 19960605     |
|    | EP 992492   | B1 | 20040825 |                   |              |
|    | R: BE, FR, GR, IT, NL, MC, IE   |    |          |                   |              |
|    | JP 2000169444   | A2 | 20000620 | JP 1999-235727    | 19960605     |
|    | JP 2000204048   | A2 | 20000725 | JP 1999-43437     | 19960605     |
|    | EE 200000317  | A  | 20010615 | EE 2000-200000317 | 19960605     |
|    | ES 2170628  | A1 | 20020801 | ES 1999-50069     | 19960605     |
|    | ES 2170628  | B1 | 20030616 |                   |              |
|    | SG 94343  | A1 | 20030218 | SG 1999-6131      | 19960605     |
|    | SG 94722  | A1 | 20030318 | SG 1999-6130      | 19960605     |
|    | NZ 510086   | A  | 20030328 | NZ 1996-510086    | 19960605     |
|    | CZ 292529   | B6 | 20031015 | CZ 1997-2330      | 19960605     |
|    | SG 99293  | A1 | 20031027 | SG 1999-5533      | 19960605     |
|    | IL 134562   | A1 | 20040620 | IL 1996-134562    | 19960605     |
|    | EP 1433781  | A1 | 20040630 | EP 2004-7801      | 19960605     |
|    | R: BE, FR, GR, IT, NL, MC, IE   |    |          |                   |              |
|    | CN 1542001  | A  | 20041103 | CN 2004-10001996  | 19960605     |
|    | TR 200001644  | T2 | 20041221 | TR 2000-200001644 | 19960605     |
|    | CZ 295106   | B6 | 20050518 | CZ 2000-315       | 19960605     |
|    | RU 2269514  | C2 | 20060210 | RU 2000-115383    | 19960605     |
|    | TW 453992   | B  | 20010911 | TW 1996-85113067  | 19961024     |
|    | ZA 9608984  | A  | 19980625 | ZA 1996-8984      | 19961025     |
|    | ZA 9608983  | A  | 19980727 | ZA 1996-8983      | 19961025     |
|    | FI 9604328  | A  | 19961230 | FI 1996-4328      | 19961028 <-- |
|    | SE 9604098  | A  | 19961208 | SE 1996-4098      | 19961108 <-- |
|    | SE 523522   | C2 | 20040427 |                   |              |
|    | US 5795908  | A  | 19980818 | US 1997-787161    | 19970123     |
|    | US 6140357  | A  | 20001031 | US 1997-833629    | 19970408     |
|    | NO 9704213  | A  | 19971204 | NO 1997-4213      | 19970912 <-- |
|    | NO 317447   | B1 | 20041101 |                   |              |
|    | BG 103977   | A  | 20001130 | BG 1999-103977    | 19971127     |
|    | LV 11991  | B  | 19980720 | LV 1997-243       | 19971203     |

|      |                 |    |          |    |             |          |
|------|-----------------|----|----------|----|-------------|----------|
| LT   | 4484            | B  | 19990325 | LT | 1998-1      | 19980106 |
| HK   | 1013287         | A1 | 20000616 | HK | 1998-114580 | 19981222 |
| HK   | 1022307         | A1 | 20010803 | HK | 2000-100914 | 19981222 |
| AU   | 9935062         | A1 | 19990819 | AU | 1999-35062  | 19990615 |
| AU   | 742575          | B2 | 20020110 |    |             |          |
| AU   | 9935063         | A1 | 19990819 | AU | 1999-35063  | 19990615 |
| AU   | 733685          | B2 | 20010524 |    |             |          |
| SE   | 9903136         | A  | 19990906 | SE | 1999-3136   | 19990906 |
| SE   | 527193          | C2 | 20060117 |    |             |          |
| DK   | 9901518         | A  | 19991022 | DK | 1999-1518   | 19991022 |
| DK   | 9901519         | A  | 19991022 | DK | 1999-1519   | 19991022 |
| US   | 6500959         | B1 | 20021231 | US | 2000-605475 | 20000628 |
| GR   | 3035326         | T3 | 20010430 | GR | 2001-400154 | 20010131 |
| US   | 2004049046      | A1 | 20040311 | US | 2002-219887 | 20020816 |
| PT   | 102940          | A  | 20030930 | PT | 2003-102940 | 20030414 |
| SE   | 2004000359      | A  | 20040217 | SE | 2004-359    | 20040217 |
| US   | 2005272780      | A1 | 20051208 | US | 2005-166220 | 20050627 |
| PRAI | US 1995-479436  | A2 | 19950607 |    |             |          |
|      | US 1996-650461  | A  | 19960521 |    |             |          |
|      | AU 1996-61062   | A3 | 19960605 |    |             |          |
|      | CA 1996-2206799 | A3 | 19960605 |    |             |          |
|      | EP 1996-918384  | A3 | 19960605 |    |             |          |
|      | EP 1999-126231  | A3 | 19960605 |    |             |          |
|      | GB 1996-24257   | A3 | 19960605 |    |             |          |
|      | IL 1996-121621  | A3 | 19960605 |    |             |          |
|      | JP 1997-501958  | A3 | 19960605 |    |             |          |
|      | RU 1997-111860  | A3 | 19960605 |    |             |          |
|      | WO 1996-US9701  | W  | 19960605 |    |             |          |
|      | US 1997-833629  | A1 | 19970408 |    |             |          |
|      | US 2000-605475  | A1 | 20000628 |    |             |          |
|      | US 2002-219887  | B3 | 20020816 |    |             |          |

OS MARPAT 130:110640

RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

| PATENT NO.   | KIND  | DATE     | APPLICATION NO.  | DATE         |
|--|-------|----------|------------------|--------------|
| -----  | ----- | -----    | -----            | -----        |
| PI US 5859031  | A     | 19990112 | US 1996-650461   | 19960521     |
| US 5614547   | A     | 19970325 | US 1995-479436   | 19950607 <-- |
| CA 2206799   | AA    | 19961219 | CA 1996-2206799  | 19960605 <-- |
| CA 2206799   | C     | 20051227 |                  |              |
| CA 2352900   | AA    | 19961219 | CA 1996-2352900  | 19960605 <-- |
| WO 9640633   | A1    | 19961219 | WO 1996-US9701   | 19960605 <-- |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,<br>ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,<br>LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,<br>SE, SG |       |          |                  |              |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,<br>IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN  |       |          |                  |              |
| AU 9661062   | A1    | 19961230 | AU 1996-61062    | 19960605 <-- |
| AU 703118  | B2    | 19990318 |                  |              |
| GB 2305176   | A1    | 19970402 | GB 1996-24257    | 19960605 <-- |
| GB 2305176   | B2    | 19991222 |                  |              |
| EP 769006  | A1    | 19970423 | EP 1996-918384   | 19960605 <-- |
| EP 769006  | B1    | 20001108 |                  |              |
| R: BE, FR, GR, IE, IT, MC, NL  |       |          |                  |              |
| DE 19680256  | T     | 19970619 | DE 1996-19680256 | 19960605 <-- |
| DE 19680256  | C2    | 20030430 |                  |              |
| CH 688775  | A     | 19980313 | CH 1996-2790     | 19960605     |
| CN 1187188   | A     | 19980708 | CN 1996-194554   | 19960605     |
| GB 2324527   | A1    | 19981028 | GB 1998-15112    | 19960605     |
| GB 2324527   | B2    | 19991222 |                  |              |
| GB 2325230   | A1    | 19981118 | GB 1998-17938    | 19960605     |
| BR 9608444   | A     | 19990105 | BR 1996-8444     | 19960605     |
| GB 2332673   | A1    | 19990630 | GB 1999-5606     | 19960605     |

|                               |    |          |                   |              |
|-------------------------------|----|----------|-------------------|--------------|
| ES 2131457                    | A1 | 19990716 | ES 1996-50030     | 19960605     |
| ES 2131457                    | B1 | 20000401 |                   |              |
| JP 2000503626                 | T2 | 20000328 | JP 1997-501958    | 19960605     |
| JP 3561843                    | B2 | 20040902 |                   |              |
| EP 992492                     | A1 | 20000412 | EP 1999-126231    | 19960605     |
| EP 992492                     | B1 | 20040825 |                   |              |
| R: BE, FR, GR, IT, NL, MC, IE |    |          |                   |              |
| JP 2000169444                 | A2 | 20000620 | JP 1999-235727    | 19960605     |
| JP 2000204048                 | A2 | 20000725 | JP 1999-43437     | 19960605     |
| EE 200000317                  | A  | 20010615 | EE 2000-200000317 | 19960605     |
| ES 2170628                    | A1 | 20020801 | ES 1999-50069     | 19960605     |
| ES 2170628                    | B1 | 20030616 |                   |              |
| SG 94343                      | A1 | 20030218 | SG 1999-6131      | 19960605     |
| SG 94722                      | A1 | 20030318 | SG 1999-6130      | 19960605     |
| NZ 510086                     | A  | 20030328 | NZ 1996-510086    | 19960605     |
| CZ 292529                     | B6 | 20031015 | CZ 1997-2330      | 19960605     |
| SG 99293                      | A1 | 20031027 | SG 1999-5533      | 19960605     |
| IL 134562                     | A1 | 20040620 | IL 1996-134562    | 19960605     |
| EP 1433781                    | A1 | 20040630 | EP 2004-7801      | 19960605     |
| R: BE, FR, GR, IT, NL, MC, IE |    |          |                   |              |
| CN 1542001                    | A  | 20041103 | CN 2004-10001996  | 19960605     |
| TR 200001644                  | T2 | 20041221 | TR 2000-200001644 | 19960605     |
| CZ 295106                     | B6 | 20050518 | CZ 2000-315       | 19960605     |
| RU 2269514                    | C2 | 20060210 | RU 2000-115383    | 19960605     |
| TW 453992                     | B  | 20010911 | TW 1996-85113067  | 19961024     |
| ZA 9608984                    | A  | 19980625 | ZA 1996-8984      | 19961025     |
| ZA 9608983                    | A  | 19980727 | ZA 1996-8983      | 19961025     |
| FI 9604328                    | A  | 19961230 | FI 1996-4328      | 19961028 <-- |
| SE 9604098                    | A  | 19961208 | SE 1996-4098      | 19961108 <-- |
| SE 523522                     | C2 | 20040427 |                   |              |
| US 5795908                    | A  | 19980818 | US 1997-787161    | 19970123     |
| US 6140357                    | A  | 20001031 | US 1997-833629    | 19970408     |
| NO 9704213                    | A  | 19971204 | NO 1997-4213      | 19970912 <-- |
| NO 317447                     | B1 | 20041101 |                   |              |
| BG 103977                     | A  | 20001130 | BG 1999-103977    | 19971127     |
| LV 11991                      | B  | 19980720 | LV 1997-243       | 19971203     |
| LT 4484                       | B  | 19990325 | LT 1998-1         | 19980106     |
| HK 1013287                    | A1 | 20000616 | HK 1998-114580    | 19981222     |
| HK 1022307                    | A1 | 20010803 | HK 2000-100914    | 19981222     |
| AU 9935062                    | A1 | 19990819 | AU 1999-35062     | 19990615     |
| AU 742575                     | B2 | 20020110 |                   |              |
| AU 9935063                    | A1 | 19990819 | AU 1999-35063     | 19990615     |
| AU 733685                     | B2 | 20010524 |                   |              |
| SE 9903136                    | A  | 19990906 | SE 1999-3136      | 19990906     |
| SE 527193                     | C2 | 20060117 |                   |              |
| DK 9901518                    | A  | 19991022 | DK 1999-1518      | 19991022     |
| DK 9901519                    | A  | 19991022 | DK 1999-1519      | 19991022     |
| US 6500959                    | B1 | 20021231 | US 2000-605475    | 20000628     |
| GR 3035326                    | T3 | 20010430 | GR 2001-400154    | 20010131     |
| US 2004049046                 | A1 | 20040311 | US 2002-219887    | 20020816     |
| PT 102940                     | A  | 20030930 | PT 2003-102940    | 20030414     |
| SE 2004000359                 | A  | 20040217 | SE 2004-359       | 20040217     |
| US 2005272780                 | A1 | 20051208 | US 2005-166220    | 20050627     |

AB **Neurotrophic N-glyoxyl prolyl esters R1COC(:X)-L-Pro-O-Z** [R1 = alkyl or alkenyl optionally substituted by cycloalkyl or aryl groups; X = O, S; Z = (un)substituted alkyl or alkenyl], which have an affinity for FKBP-type immunophilins, were prepared for use as inhibitors of the enzyme activity associated with immunophilin proteins, in particular peptidyl-prolyl isomerase (rotamase) enzyme activity. Thus, 3-phenylpropyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate was prepared and showed apparent Ki value 42 for inhibition of rotamase activity.

AN 1998:599365 CAPLUS  
 DN 129:198015  
 TI Rotamase enzyme activity inhibitors  
 IN Steiner, Joseph P.; Hamilton, Gregory S.  
 PA GPI Nil Holdings, Inc., USA  
 SO U.S., 16 pp., Cont.-in-part of U. S. Ser. No. 551,026, abandoned.  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 8

|      | PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE         |
|------|---|------|----------|-----------------|--------------|
| PI   | US 5801197  | A    | 19980901 | US 1996-645149  | 19960513     |
|      | US 2002013344   | A1   | 20020131 | US 1995-551026  | 19951031     |
|      | CA 2236328  | AA   | 19970509 | CA 1996-2236328 | 19960826 <-- |
|      | WO 9716190  | A1   | 19970509 | WO 1996-US13624 | 19960826 <-- |
|      | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN |      |          |                 |              |
|      | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN  |      |          |                 |              |
|      | AU 9668573  | A1   | 19970522 | AU 1996-68573   | 19960826 <-- |
|      | AU 713302   | B2   | 19991125 |                 |              |
|      | EP 859614   | A1   | 19980826 | EP 1996-929014  | 19960826     |
|      | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI   |      |          |                 |              |
|      | CN 1205635  | A    | 19990120 | CN 1996-199127  | 19960826     |
|      | JP 11514643   | T2   | 19991214 | JP 1996-517308  | 19960826     |
|      | NO 9801903  | A    | 19980630 | NO 1998-1903    | 19980427     |
|      | LV 12102  | B    | 19981020 | LV 1998-85      | 19980625     |
| PRAI | US 1995-551026  | B2   | 19951031 |                 |              |
|      | US 1996-645149  | A    | 19960513 |                 |              |
|      | WO 1996-US13624   | W    | 19960826 |                 |              |

OS MARPAT 129:198015

RE.CNT 173 THERE ARE 173 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

|    | PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE         |
|----|---|------|----------|-----------------|--------------|
| PI | US 5801197  | A    | 19980901 | US 1996-645149  | 19960513     |
|    | US 2002013344   | A1   | 20020131 | US 1995-551026  | 19951031     |
|    | CA 2236328  | AA   | 19970509 | CA 1996-2236328 | 19960826 <-- |
|    | WO 9716190  | A1   | 19970509 | WO 1996-US13624 | 19960826 <-- |
|    | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN |      |          |                 |              |
|    | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN  |      |          |                 |              |
|    | AU 9668573  | A1   | 19970522 | AU 1996-68573   | 19960826 <-- |
|    | AU 713302   | B2   | 19991125 |                 |              |
|    | EP 859614   | A1   | 19980826 | EP 1996-929014  | 19960826     |
|    | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI   |      |          |                 |              |
|    | CN 1205635  | A    | 19990120 | CN 1996-199127  | 19960826     |
|    | JP 11514643   | T2   | 19991214 | JP 1996-517308  | 19960826     |
|    | NO 9801903  | A    | 19980630 | NO 1998-1903    | 19980427     |
|    | LV 12102  | B    | 19981020 | LV 1998-85      | 19980625     |

ST rotamase enzyme inhibitor **pyrrolidinecarboxylate**;  
neurotrophic pipecolic acid deriv

=> s (carboxylic(1)carboxylate(1)prodrug?)  
235433 CARBOXYLIC  
67489 CARBOXYLATE  
14733 PRODRUG?  
L5 22 (CARBOXYLIC(L)CARBOXYLATE(L)PRODRUG?)

=> s 15 and py<1998  
18297841 PY<1998  
L6 7 L5 AND PY<1998

=> d bib hit 1-7

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1997:805509 CAPLUS  
DN 128:136107  
TI Acyloxymethyl as a drug protecting group: part 4. The hydrolysis of tertiary amidomethyl ester prodrugs of carboxylic acid agents  
AU Iley, Jim; Moreira, Rui; Calheiros, Teresa; Mendes, Eduarda  
CS Chemistry Department, The Open University, Milton Keynes, MK7 6AA, UK  
SO Pharmaceutical Research (1997), 14(11), 1634-1639  
CODEN: PHREEB; ISSN: 0724-8741  
PB Plenum Publishing Corp.  
DT Journal  
LA English  
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT  
SO Pharmaceutical Research (1997), 14(11), 1634-1639  
CODEN: PHREEB; ISSN: 0724-8741  
AB Novel tertiary amidomethyl esters were synthesized and evaluated as potential prodrugs of carboxylic acid agents. Hydrolysis of the title compds. in buffer solns. and in plasma were studied by UV spectroscopy and HPLC. Amidomethyl esters were hydrolyzed by acid-catalyzed, base-catalyzed and pH-independent pathways. Both the acid-catalyzed,  $kH^+$ , and pH-independent processes,  $k_0$ , were strongly affected by the electronic and steric nature of the N-substituent in the pro-moiety. For both processes, the electronic effect exerted greater influence, and electron-withdrawing substituents retarded reaction. The pH-independent hydrolysis of amidomethyl esters were dependent on the  $pK_a$  of the carboxylate leaving group, giving a Bronsted  $\beta_{lg}$  value of -0.91. The base-catalyzed,  $kOH^-$ , pathway was mainly affected by the steric bulk of the nitrogen substituents in the amide moiety, the reactivity being reduced with larger N-substituents. Hydrolysis in human plasma appeared to be mediated by enzymic processes and is dependent upon the steric bulk in the carboxylic acid moiety. Plasma hydrolysis rates were inversely dependent on the lipophilicity of the ester. Derivs. containing the Et hippurate carrier are useful prodrugs for carboxylic acid-containing drugs with  $pK_a > 3,5$ , such as non-steroidal anti-inflammatory agents and valproic acid.

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1997:140702 CAPLUS  
DN 126:126494  
TI Ortho-Substituted Benzofused Macroyclic Lactams as Zinc Metalloprotease Inhibitors  
AU Ksander, Gary M.; de Jesus, Reynalda; Yuan, Andrew; Ghai, R. D.; Trapani, A.; McMartin, Colin; Bohacek, Regine  
CS Res. Dep., Novartis Pharm. Corp., Summit, NJ, 07901, USA  
SO Journal of Medicinal Chemistry (1997), 40(4), 495-505  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English  
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

SO Journal of Medicinal Chemistry (1997), 40(4), 495-505  
CODEN: JMCMAR; ISSN: 0022-2623  
AB The design and preparation of ortho-substituted benzofused macrocyclic lactams are described. The benzofused macrocyclic lactams were designed as neutral endopeptidase 24.11 (NEP) inhibitors. Docking studies were carried out in a model of thermolysin (TLN) using the MACROMODEL and QXP modeling programs to select suitable ring sizes. These studies predicted that the 11-, 12-, and 13-membered ring macrocyclic lactams would be active in both enzymes TLN and NEP. Good predictability of exptl. results, within this series, of binding to thermolysin and to a lesser extent to NEP was observed. A visual comparison, docked at the active site of TLN, is presented for thiorphan, a 10-membered ring macrocycle and an 11-membered ring benzofused macrocyclic lactam. Potent inhibition of both NEP and thermolysin was obtained. The 11-membered ring macrocycle, 2,3,4,5,6,7,8,9-octahydro-2(S)-mercapto-3-oxo-1H-4-benzazacycloundecine-5(S)-carboxylic acid, is the most potent inhibitor from this series of compds. (TLN IC<sub>50</sub> = 68 nM; NEP IC<sub>50</sub> = 0.9 nM). The effects of prodrug benzyl 2(R)-[(acetylthio)methyl]-2,3,4,5,6,7,8,9,10,11-decahydro-2-ox-1H-4-benzazacyclotridecine-5(S)-carboxylate administered at 10 mg/kg po on plasma atrial natriuretic peptide (ANP) levels in conscious rats was greater than 200% over a 4 h period.

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1997:21631 CAPLUS  
DN 126:69906  
TI Angiotensin II-inhibitory action of candesartan cilexetil and its active metabolite, CV-11974, in rabbit aortic strips and conscious rats  
AU Shibouta, Yumiko; Inada, Yoshiyuki; Ojima, Mami; Wada, Takeo; Noda, Masakuni; Sanada, Tsukasa; Kubo, Keiji; Kohara, Yasuhisa; Naka, Takehiko; Nishikawa, Kohei  
CS Pharmaceutical Res. Div., Takeda Chem. Ind., Ltd., Japan  
SO Yakuri to Chiryo (1996), 24(10), 2207-2213  
CODEN: YACHDS; ISSN: 0386-3603  
PB Raifu Saiensu Shuppan K.K.  
DT Journal  
LA Japanese  
SO Yakuri to Chiryo (1996), 24(10), 2207-2213  
CODEN: YACHDS; ISSN: 0386-3603  
AB The angiotensin II (AII) antagonistic action of 2-ethoxy-1-[(2'-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974) was examined in an in vitro AII-induced contraction assay using rabbit aortic strips, and that of CV-11974 and its prodrug, (±)1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[(2'-(1H-tetrazol-5-yl) biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylate (candesartan cilexetil:TCV-116), was examined in an in vivo assay system of AII-induced pressor response in conscious rats. CV-11974 selectively inhibited the AII-induced contraction of rabbit aortic strips in a noncompetitive manner (pD<sub>2</sub>:10.08), but at 10 μM it has no effects on the contraction induced by norepinephrine, KCl, serotonin, prostaglandin F2α, or endothelin. EXP3174, a main metabolite of losartan, showed a mixed type of competitive and noncompetitive inhibition with a pD<sub>2</sub> value of 9.06 and a pA<sub>2</sub> value of 10.20 for the AII-induced contraction. CV-11974 given i.v. and TCV-116 given orally inhibited the AII-induced pressor response in rats with ID<sub>50</sub> values of 0.03 mg/kg and 0.07 mg/kg, resp. These effects of CV-11974 and TCV-116 were approx. 10 times and 40 times more potent than those of EXP3174 and losartan, resp. These results indicate that CV-11947 is a highly potent and selective AII antagonist and TCV-116 has a long-acting AII-inhibitory action in the rat.

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1996:515414 CAPLUS  
DN 125:276411  
TI Synthesis and antiviral activity of N-4'-dihydropyridinyl and

dihydroquinolinylcarbonyl-2-hydroxymethyl-5-[cytosin-1'-yl]-1,3-oxathiolane derivatives against human immunodeficiency virus and duck hepatitis B virus

AU Camplo, M.; Charvey-Faury, A. S.; Borel, C.; Turin, F.; Hantz, O.; Traubaud, C.; Niddam, V.; Mourier, N.; Graciet, J. C.; et al.

CS Laboratoire de Chimie Biomoleculaire, Faculte des Sciences de Luminy, Marseille, 13288, Fr.

SO European Journal of Medicinal Chemistry (1996), 31(7-8), 539-546

CODEN: EJMCA5; ISSN: 0223-5234

PB Elsevier

DT Journal

LA English

SO European Journal of Medicinal Chemistry (1996), 31(7-8), 539-546

CODEN: EJMCA5; ISSN: 0223-5234

AB Dihydropyridine and dihydroquinoline derivs. of 2-hydroxymethyl-5-[cytosin-1'-yl]-1,3-oxathiolane (( $\pm$ )-3TC) have been prepared. The N-4-nicotinate or the N-4-quinoline-**carboxylate** amides were obtained by reacting nicotinic or quinoline-**carboxylic** acids with ( $\pm$ )-3TC in the presence of DCC and HOBT. These derivs. were converted into their corresponding N-methylpyridinium and N-Me quinolinium salts by treatment with MeI in acetone. Reduction of the latter with Na2S2O4 gave dihydropyridine and dihydroquinoline compds. The N-4-trifluorotoluidinonicotinate derivative was obtained from the coupling of niflumic acid and ( $\pm$ )-3TC using BOP and DIEA. The anti-HIV-1-activities of seven derivs. were determined in MT-4 infected cell cultures. Of these compds., the IC50 values ranged from 0.1-100  $\mu$ M, while the IC50 for ( $\pm$ )-3TC was 0.1  $\mu$ M. The anti-HBV activities were determined in infected duck hepatocytes. Anti-HBV activities of the ( $\pm$ )-3TC derivs. were half that of the parent drug ( $\pm$ )-3TC. The lipophilicity (partition coeffs.) of these compds. were determined. The dihydroquinoline prodrugs had greater lipophilicity than the dihydropyridine analogs.

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:521057 CAPLUS

DN 122:281858

TI Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells

AU Flesch, Markus; Ko, Yon; Seul, Claudia; Duesing, Rainer; Feltkamp, Heinrich; Vetter, Hans; Sachinidis, Agapios

CS Medizinische Universitaets-Poliklinik, Wilhelmstr. 35-37, Bonn, 53111, Germany

SO European Journal of Pharmacology, Molecular Pharmacology Section (1995), 289(2), 399-402

CODEN: EJPPE; ISSN: 0922-4106

PB Elsevier

DT Journal

LA English

SO European Journal of Pharmacology, Molecular Pharmacology Section (1995), 289(2), 399-402

CODEN: EJPPE; ISSN: 0922-4106

AB ( $\pm$ )-1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-**carboxylate** (TCV-116, Candesartan) and its active metabolite 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-**carboxylic** acid (CV-11974) are specific nonpeptide angiotensin AT1 receptor antagonists. In the present study, the inhibitory potency of these two antagonists on the angiotensin II-induced responses in aortic vascular smooth muscle cells from Wistar Kyoto rats was investigated. The specific binding of 125I-angiotensin II to cells was inhibited by CV-11974 and TCV-116 with a half-maximal inhibitory concentration (IC50) of  $3+10^{-11}$  M and  $1+10^{-9}$  M, resp. CV-11974 and TCV-116 inhibited the angiotensin II-induced increase in [<sup>3</sup>H]thymidine incorporation with an IC50 of  $3+10^{-10}$  and  $5+10^{-9}$  M, resp. Both CV-11974 and TCV-116 ( $10^{-7}$

M) completely blocked the angiotensin II-induced increase in c-fos mRNA. The inhibitory potency of the metabolite CV-11974 was about 30-100-fold higher than that of the prodrug TCV-116.

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1993:580705 CAPLUS  
DN 119:180705  
TI Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids  
AU Kubo, Keiji; Kohara, Yasuhisa; Yoshimura, Yoshinobu; Inada, Yoshiyuki; Shibouta, Yumiko; Furukawa, Yoshiyasu; Kato, Takeshi; Nishikawa, Kohei; Naka, Takehiko  
CS Pharm. Res. Div., Takeda Chem. Ind., Ltd., Osaka, 532, Japan  
SO Journal of Medicinal Chemistry (1993), 36(16), 2343-9  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
SO Journal of Medicinal Chemistry (1993), 36(16), 2343-9  
CODEN: JMCMAR; ISSN: 0022-2623  
AB In order to improve the oral bioavailability (BA) of 2-butyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylic acid (CV-11194; I; R = Bu) and 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974; I; R = OEt), novel angiotensin II (AII) receptor antagonists, chemical modification to yield prodrugs has been examined. After selective tritylation of the tetrazole rings in I, treatment of N-tritylated benzimidazole-7-carboxylic acids II with a variety of alkyl halides, followed by deprotection with hydrochloric acid, afforded esters of I. Mainly 1-(acyloxy)alkyl esters and 1-[(alkoxycarbonyl)oxy]alkyl esters, double ester derivs., were synthesized. Their inhibitory effect on AII-induced pressor response in rats and oral BA were investigated. (Pivaloyloxy)methyl and ( $\pm$ )-1-[(cyclohexyloxy)carbonyl]oxyethyl esters of I showed marked increases in oral bioavailability which significantly potentiated the inhibitory effect of the parent compds. on AII-induced pressor response. Among them, ( $\pm$ )-1-[(cyclohexyloxy)carbonyl]oxyethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylate (III, TCV-116) was selected as a candidate for clin. evaluation.

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1993:573923 CAPLUS  
DN 119:173923  
TI Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, ( $\pm$ )-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylate (TCV-116)  
AU Shibouta, Yumiko; Inada, Yoshiyuki; Ojima, Mami; Wada, Takeo; Noda, Masakuni; Sanada, Tsukasa; Kubo, Keiji; Kohara, Yasuhisa; Naka, Takehiko; Nishikawa, Kohei  
CS Pharm. Res. Div., Takeda Chem. Ind., Osaka, Japan  
SO Journal of Pharmacology and Experimental Therapeutics (1993), 266(1), 114-20  
CODEN: JPETAB; ISSN: 0022-3565  
DT Journal  
LA English  
TI Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, ( $\pm$ )-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-benzimidazole-7-carboxylate (TCV-116)  
SO Journal of Pharmacology and Experimental Therapeutics (1993),

(FILE 'HOME' ENTERED AT 10:30:26 ON 07 MAR 2006)

FILE 'CAPLUS' ENTERED AT 10:34:21 ON 07 MAR 2006

L1 31 S NEUROTROPH? (L) PYRROLIDIN?  
L2 4 S L1 AND PY<1998  
L3 0 S PYROLIDIN? (L) (CARBOXYLIC (L) CARBOXYLATE (L) PRODRUG?)  
L4 0 S NEUROTROPH? AND (CARBOXYLIC (L) CARBOXYLATE (L) PRODRUG?)  
L5 22 S (CARBOXYLIC (L) CARBOXYLATE (L) PRODRUG?)  
L6 7 S L5 AND PY<1998  
L7 ANALYZE L2 4 RN : 26 TERMS

FILE 'REGISTRY' ENTERED AT 10:40:29 ON 07 MAR 2006

L8 26 S L7  
L9 0 S L8 AND PYRROLIDIN?

=> fil caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
CA SUBSCRIBER PRICE

|  | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST                        | 5.20             | 78.64         |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE                        | 0.00             | -6.75         |

FILE 'CAPLUS' ENTERED AT 10:41:08 ON 07 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Mar 2006 VOL 144 ISS 11  
FILE LAST UPDATED: 6 Mar 2006 (20060306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> analyze 12  
ENTER ANSWER NUMBER OR RANGE (1-) :1-3  
ENTER DISPLAY CODE (TI) OR ?:rn  
L10 ANALYZE L2 1-3 RN : 173 TERMS

=> fil reg  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
CA SUBSCRIBER PRICE

|  | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST                        | 11.31            | 89.95         |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE                        | 0.00             | -6.75         |

FILE 'REGISTRY' ENTERED AT 10:41:23 ON 07 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3  
DICTIONARY FILE UPDATES: 6 MAR 2006 HIGHEST RN 876011-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>


```
=> s l10
L11      173 L10

=> s l11 and pyrrolidin?
      548140 PYRROLIDIN?
L12      18 L11 AND PYRROLIDIN?

=> d scan

L12 18 ANSWERS  REGISTRY  COPYRIGHT 2006 ACS on STN
IN  1-Pyrrolidineacetic acid,  $\alpha$ -oxo-2-[1-oxo-5-phenyl-2-(3-
      phenylpropyl)pentyl]-, methyl ester, (2S)- (9CI)
MF  C27 H33 N O4
```

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):17

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Pyrrolidinecarboxamide, 1-(3,3-dimethyl-1,2-dioxopentyl)-N-[3-(3-pyridinyl)propyl]-, (2S)- (9CI)  
MF C20 H29 N3 O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Pyrrolidinecarboxamide, 1-(3,3-dimethyl-1,2-dioxopentyl)-N-[3-phenyl-1-(2-phenylethyl)propyl]-, (2S)- (9CI)  
MF C29 H38 N2 O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1-Pyrrolidineacetic acid, 2-(methoxycarbonyl)- $\alpha$ -oxo-, methyl ester, (2S)- (9CI)  
MF C9 H13 N O5


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1-Pyrrolidinecarboxylic acid, 2-[1-oxo-4-phenyl-2-(2-phenylethyl)butyl]-, 1,1-dimethylethyl ester, (2S)- (9CI)  
 MF C27 H35 N O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2-Pyrrolidinecarboxamide, 1-(3,3-dimethyl-1,2-dioxopentyl)-N-(4-phenylbutyl)-, (2S)- (9CI)  
 MF C22 H32 N2 O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Pyrrolidine, 1-(3,3-dimethyl-1,2-dioxopentyl)-2-[1-oxo-4-phenyl-2-(2-phenylethyl)butyl]-, (2S)- (9CI)  
 MF C29 H37 N O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1-Pyrrolidineacetic acid, 2-carboxy- $\alpha$ -oxo-,  $\alpha$ -ethyl  
ester, (2S)- (9CI)  
MF C9 H13 N O5  
CI COM


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Pyrrolidinecarboxamide, 1-(3,3-dimethyl-1,2-dioxopentyl)-N-[3-(4-  
hydroxyphenyl)propyl]-, (2S)- (9CI)  
MF C21 H30 N2 O4


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2-Pyrrolidinecarboxamide, 1-(3,3-dimethyl-1,2-dioxobutyl)-N-(3-phenylpropyl)-, (2S)- (9CI)  
 MF C20 H28 N2 O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-, methyl ester (9CI)  
 MF C13 H21 N O4

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1-Pyrrolidineacetic acid,  $\alpha$ -oxo-2-[1-oxo-4-phenyl-2-(2-phenylethyl)butyl]-, methyl ester, (2S)- (9CI)

MF C25 H29 N O4

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 2-Pyrrolidinecarboxamide, 1-(3,3-dimethyl-1,2-dioxopentyl)-N-(3,3-diphenylpropyl)-, (2S)- (9CI)

MF C27 H34 N2 O3

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Pyrrolidine, 1-(3,3-dimethyl-1,2-dioxopentyl)-2-[1-oxo-5-phenyl-2-(3-phenylpropyl)pentyl]-, (2S)- (9CI)

MF C31 H41 N O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1-Pyrrolidinecarboxylic acid, 2-formyl-, 1,1-dimethylethyl ester,  
(2S)- (9CI)  
MF C10 H17 N O3


Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1-Pyrrolidinecarboxylic acid, 2-[1-hydroxy-4-phenyl-2-(2-phenylethyl)butyl]-, 1,1-dimethylethyl ester, (2S)- (9CI)  
MF C27 H37 N O3


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Pyrrolidinecarboxamide, 1-(3,3-dimethyl-1,2-dioxopentyl)-N-(2-phenylethyl)-, (2S)- (9CI)  
MF C20 H28 N2 O3


Absolute stereochemistry.



• \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L12 18 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)- (9CI)  
MF C12 H19 N O4

Absolute stereochemistry.



• \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED